VOYAGER THERAPEUTICSABOUT USOUR APPROACH PROGRAMSPATIENTS CAREGIVERSJOIN OUR TEAMCONTACTOUR CLINICAL TRIALS April 29, 2019. Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting. March 28, 2019. Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology.

MANAGEMENT TEAM

Management Team. Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies. Management Team. Founders. Board of Directors. PIPELINE | VOYAGER THERAPEUTICS Developing life-changing gene therapies for devastating neurological diseases. Voyager’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the

brain.

INVESTOR OVERVIEW

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. VOYAGER THERAPEUTICS ANNOUNCES FIRST QUARTER 2021 - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021- 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids- Virtual investor and analyst event to be held in July 2021 CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Voyager VOYAGER THERAPEUTICS RECEIVES FDA CLEARANCE OF IND One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass. , April 26, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, DIRECTOR, EXTERNAL MANUFACTURING AND SUPPLY Voyager is seeking Director, External Manufacturing and Supply who will manage multiple CMC projects with CMOs, as well as the overall Supply Chain network for clinical material distribution. This role leads external manufacturing function at Voyager and assists the cross-functional interaction among the internal development team

(process

VOYAGER THERAPEUTICS’ NOVEL CAPSIDS DEMONSTRATE ROBUST Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration; CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on

PRESENTATIONS

The Investor Relations website contains information about Voyager Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. CORPORATE PRESENTATION Forward-Looking Statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The

Private Securities

VOYAGER THERAPEUTICSABOUT USOUR APPROACH PROGRAMSPATIENTS CAREGIVERSJOIN OUR TEAMCONTACTOUR CLINICAL TRIALS April 29, 2019. Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting. March 28, 2019. Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology.

MANAGEMENT TEAM

Management Team. Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies. Management Team. Founders. Board of Directors. PIPELINE | VOYAGER THERAPEUTICS Developing life-changing gene therapies for devastating neurological diseases. Voyager’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the

brain.

INVESTOR OVERVIEW

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. VOYAGER THERAPEUTICS ANNOUNCES FIRST QUARTER 2021 - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021- 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids- Virtual investor and analyst event to be held in July 2021 CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Voyager VOYAGER THERAPEUTICS RECEIVES FDA CLEARANCE OF IND One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass. , April 26, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, DIRECTOR, EXTERNAL MANUFACTURING AND SUPPLY Voyager is seeking Director, External Manufacturing and Supply who will manage multiple CMC projects with CMOs, as well as the overall Supply Chain network for clinical material distribution. This role leads external manufacturing function at Voyager and assists the cross-functional interaction among the internal development team

(process

VOYAGER THERAPEUTICS’ NOVEL CAPSIDS DEMONSTRATE ROBUST Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration; CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on

PRESENTATIONS

The Investor Relations website contains information about Voyager Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. CORPORATE PRESENTATION Forward-Looking Statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The

Private Securities

PIPELINE | VOYAGER THERAPEUTICS Developing life-changing gene therapies for devastating neurological diseases. Voyager’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the

brain.

OUR PROGRAMS

Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease that affects approximately 1 million people in the U.S. and 6 million people worldwide. 1 Parkinson’s disease is characterized by a loss of dopamine and its function. Dopamine is a chemical “messenger” that is produced in the brain and is involved in the control of movement. TRACER | VOYAGER THERAPEUTICS Innovative, next-generation AAV capsid platform. Voyager’s proprietary RNA-based functional screening technology, TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA), uses a directed evolution approach in non-human primates to identify novel capsids with improved ability to target specific cells and tissues that are often difficult to reach with current gene therapy

INVESTOR OVERVIEW

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. PARKINSON’S DISEASE CLINICAL TRIAL The RESTORE-1, Phase 2, randomized, placebo-surgery controlled, double-blinded, multi-center clinical trial was designed to evaluate the safety and efficacy of VY-AADC for the potential treatment of advancing Parkinson’s disease. The RESTORE-1 trial has been placed on clinical hold by the U.S. Food and Drug Administration following

the

VOYAGER THERAPEUTICS ANNOUNCES FIRST QUARTER 2021 - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021- 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids- Virtual investor and analyst event to be held in July 2021 CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Voyager

BOARD OF DIRECTORS

Michael Higgins (Chair) Board of Directors, Pulmatrix and Genocea Biosciences. Michael is the chair of our board of directors. He is also the chair of the board of Pulmatrix, Inc. and a board member at Genocea Biosciences, Nocion Therapeutics, Camp4 Therapeutics and Sea Pharmaceuticals. Previously, Michael served as entrepreneur-in-residence at VOYAGER THERAPEUTICS PROVIDES UPDATE ON ABBVIE VECTORIZED CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie. Voyager retains full rights to the vectorization VOYAGER THERAPEUTICS ANNOUNCES RESTRUCTURED GENE THERAPY Gains worldwide rights to VY-HTT01 for Huntington ’s disease Resources to be reallocated to VY-HTT01 and other programs; intends to seek a partner for the SOD1 ALS program CAMBRIDGE, Mass. , June 17, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. VOYAGER THERAPEUTICS ANNOUNCES PRECLINICAL DATA FOR Data presentations at this year’s ESGCT meeting can be found on the Events and Presentations page of the Investors and Media section of Voyager’s corporate website at www.voyagertherapeutics.com . About Voyager Therapeutics. Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. VOYAGER THERAPEUTICSABOUT USOUR APPROACH PROGRAMSPATIENTS CAREGIVERSJOIN OUR TEAMCONTACTOUR CLINICAL TRIALS April 29, 2019. Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting. March 28, 2019. Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology.

MANAGEMENT TEAM

Management Team. Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies. Management Team. Founders. Board of Directors. PIPELINE | VOYAGER THERAPEUTICS Developing life-changing gene therapies for devastating neurological diseases. Voyager’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the

brain.

PRESS RELEASES

Press Releases. May 19, 2021. Voyager Therapeutics Announces Strategic Shift and Leadership Transitions. May 12, 2021. Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody. May 11, 2021. Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the

Blood Brain

INVESTOR OVERVIEW

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques.

BOARD OF DIRECTORS

Michael Higgins (Chair) Board of Directors, Pulmatrix and Genocea Biosciences. Michael is the chair of our board of directors. He is also the chair of the board of Pulmatrix, Inc. and a board member at Genocea Biosciences, Nocion Therapeutics, Camp4 Therapeutics and Sea Pharmaceuticals. Previously, Michael served as entrepreneur-in-residence at DIRECTOR, EXTERNAL MANUFACTURING AND SUPPLY Voyager is seeking Director, External Manufacturing and Supply who will manage multiple CMC projects with CMOs, as well as the overall Supply Chain network for clinical material distribution. This role leads external manufacturing function at Voyager and assists the cross-functional interaction among the internal development team

(process

VOYAGER THERAPEUTICS’ NOVEL CAPSIDS DEMONSTRATE ROBUST Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration; CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on VOYAGER THERAPEUTICS RECEIVES FDA CLEARANCE OF IND One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass. , April 26, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, VOYAGER THERAPEUTICS PROVIDES UPDATE ON NBIB-1817 (VY-AADC CAMBRIDGE, Mass. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the Parkinson’s disease portion of the collaboration agreement, effective August 2, 2021 . VOYAGER THERAPEUTICSABOUT USOUR APPROACH PROGRAMSPATIENTS CAREGIVERSJOIN OUR TEAMCONTACTOUR CLINICAL TRIALS April 29, 2019. Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting. March 28, 2019. Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology.

MANAGEMENT TEAM

Management Team. Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies. Management Team. Founders. Board of Directors. PIPELINE | VOYAGER THERAPEUTICS Developing life-changing gene therapies for devastating neurological diseases. Voyager’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the

brain.

PRESS RELEASES

Press Releases. May 19, 2021. Voyager Therapeutics Announces Strategic Shift and Leadership Transitions. May 12, 2021. Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody. May 11, 2021. Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the

Blood Brain

INVESTOR OVERVIEW

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques.

BOARD OF DIRECTORS

Michael Higgins (Chair) Board of Directors, Pulmatrix and Genocea Biosciences. Michael is the chair of our board of directors. He is also the chair of the board of Pulmatrix, Inc. and a board member at Genocea Biosciences, Nocion Therapeutics, Camp4 Therapeutics and Sea Pharmaceuticals. Previously, Michael served as entrepreneur-in-residence at DIRECTOR, EXTERNAL MANUFACTURING AND SUPPLY Voyager is seeking Director, External Manufacturing and Supply who will manage multiple CMC projects with CMOs, as well as the overall Supply Chain network for clinical material distribution. This role leads external manufacturing function at Voyager and assists the cross-functional interaction among the internal development team

(process

VOYAGER THERAPEUTICS’ NOVEL CAPSIDS DEMONSTRATE ROBUST Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration; CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on VOYAGER THERAPEUTICS RECEIVES FDA CLEARANCE OF IND One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass. , April 26, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, VOYAGER THERAPEUTICS PROVIDES UPDATE ON NBIB-1817 (VY-AADC CAMBRIDGE, Mass. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the Parkinson’s disease portion of the collaboration agreement, effective August 2, 2021 . ABOUT US | VOYAGER THERAPEUTICS One-Time Delivery. Benefits for a lifetime.

MANAGEMENT TEAM

Management Team. Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies. Management Team. Founders. Board of Directors.

OUR PROGRAMS

Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease that affects approximately 1 million people in the U.S. and 6 million people worldwide. 1 Parkinson’s disease is characterized by a loss of dopamine and its function. Dopamine is a chemical “messenger” that is produced in the brain and is involved in the control of movement.

INVESTOR OVERVIEW

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. PARKINSON’S DISEASE CLINICAL TRIAL The RESTORE-1, Phase 2, randomized, placebo-surgery controlled, double-blinded, multi-center clinical trial was designed to evaluate the safety and efficacy of VY-AADC for the potential treatment of advancing Parkinson’s disease. The RESTORE-1 trial has been placed on clinical hold by the U.S. Food and Drug Administration following

the

CAREERS | VOYAGER THERAPEUTICS Note to Employment Agencies: Please do not forward agency resumes. Voyager Therapeutics is not responsible for any fees related to resumes that are unsolicited and out of executed contracts.

MANUFACTURING

The ability to produce and manufacture high-quality AAV vectors at scale is a critical success factor in AAV gene therapy. Several members of Voyager Therapeutics’ current production team invented and developed the baculovirus AAV production system, a technology for producing AAV vectors at scale in insect-derived cells, which we use and have continued to improve.

PRESENTATIONS

The Investor Relations website contains information about Voyager Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. ABOUT FRIEDREICH’S ATAXIA AND VY-FXN01 One-Time Delivery. Benefits for a lifetime.

2019 ANNUAL REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December

31, 2019 OR

VOYAGER THERAPEUTICSABOUT USOUR APPROACH PROGRAMSPATIENTS CAREGIVERSJOIN OUR TEAMCONTACTOUR CLINICAL TRIALS April 29, 2019. Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting. March 28, 2019. Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology.

MANAGEMENT TEAM

Management Team. Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies. Management Team. Founders. Board of Directors. PIPELINE | VOYAGER THERAPEUTICS Developing life-changing gene therapies for devastating neurological diseases. Voyager’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the

brain.

OUR PROGRAMS

Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease that affects approximately 1 million people in the U.S. and 6 million people worldwide. 1 Parkinson’s disease is characterized by a loss of dopamine and its function. Dopamine is a chemical “messenger” that is produced in the brain and is involved in the control of movement.

PRESS RELEASES

Press Releases. May 12, 2021. Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody. May 11, 2021. Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates. May 10, 2021. FOUNDERS | VOYAGER THERAPEUTICSVOYAGER THERAPEUTICS PRESENTATIONVOYAGER THERAPEUTICS STOCKVOYAGER THERAPEUTICS CAMBRIDGE MAVOYAGER THERAPEUTICS PARKINSON SVOYAGER THERAPEUTICS STOCK PRICE He is one of the founders of the American Society of Gene and Cell Therapy, served as its president from 2005 to 2006, and was the recipient of the society’s Outstanding Investigator Award in 2013. Dr. Kay received the E. Mead Johnson Award for Research in Pediatrics

in 2000.

BOARD OF DIRECTORS

Michael Higgins (Chair) Board of Directors, Pulmatrix and Genocea Biosciences. Michael is the chair of our board of directors. He is also the chair of the board of Pulmatrix, Inc. and a board member at Genocea Biosciences, Nocion Therapeutics, Camp4 Therapeutics and Sea Pharmaceuticals. Previously, Michael served as entrepreneur-in-residence at DIRECTOR, EXTERNAL MANUFACTURING AND SUPPLY Director, External Manufacturing and Supply. Voyager Therapeutics is developing recombinant adeno-associated virus (rAAV) vectors for treating neurological diseases. VOYAGER THERAPEUTICS’ NOVEL CAPSIDS DEMONSTRATE ROBUST Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration; CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on VOYAGER THERAPEUTICS & GENZYME ANNOUNCE MAJOR STRATEGIC Up to $845 Million Collaboration to Support Development, Expansion and Commercialization of Voyager’s Novel CNS Product Pipeline. Cambridge, Mass., February 11, 2015 – Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), and Genzyme, a Sanofi company and gene VOYAGER THERAPEUTICSABOUT USOUR APPROACH PROGRAMSPATIENTS CAREGIVERSJOIN OUR TEAMCONTACTOUR CLINICAL TRIALS April 29, 2019. Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting. March 28, 2019. Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology.

MANAGEMENT TEAM

Management Team. Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies. Management Team. Founders. Board of Directors. PIPELINE | VOYAGER THERAPEUTICS Developing life-changing gene therapies for devastating neurological diseases. Voyager’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington’s disease, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the

brain.

OUR PROGRAMS

Parkinson’s disease is a chronic, progressive and debilitating neurodegenerative disease that affects approximately 1 million people in the U.S. and 6 million people worldwide. 1 Parkinson’s disease is characterized by a loss of dopamine and its function. Dopamine is a chemical “messenger” that is produced in the brain and is involved in the control of movement.

PRESS RELEASES

Press Releases. May 12, 2021. Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody. May 11, 2021. Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates. May 10, 2021. FOUNDERS | VOYAGER THERAPEUTICSVOYAGER THERAPEUTICS PRESENTATIONVOYAGER THERAPEUTICS STOCKVOYAGER THERAPEUTICS CAMBRIDGE MAVOYAGER THERAPEUTICS PARKINSON SVOYAGER THERAPEUTICS STOCK PRICE He is one of the founders of the American Society of Gene and Cell Therapy, served as its president from 2005 to 2006, and was the recipient of the society’s Outstanding Investigator Award in 2013. Dr. Kay received the E. Mead Johnson Award for Research in Pediatrics

in 2000.

BOARD OF DIRECTORS

Michael Higgins (Chair) Board of Directors, Pulmatrix and Genocea Biosciences. Michael is the chair of our board of directors. He is also the chair of the board of Pulmatrix, Inc. and a board member at Genocea Biosciences, Nocion Therapeutics, Camp4 Therapeutics and Sea Pharmaceuticals. Previously, Michael served as entrepreneur-in-residence at DIRECTOR, EXTERNAL MANUFACTURING AND SUPPLY Director, External Manufacturing and Supply. Voyager Therapeutics is developing recombinant adeno-associated virus (rAAV) vectors for treating neurological diseases. VOYAGER THERAPEUTICS’ NOVEL CAPSIDS DEMONSTRATE ROBUST Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration; CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on VOYAGER THERAPEUTICS & GENZYME ANNOUNCE MAJOR STRATEGIC Up to $845 Million Collaboration to Support Development, Expansion and Commercialization of Voyager’s Novel CNS Product Pipeline. Cambridge, Mass., February 11, 2015 – Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), and Genzyme, a Sanofi company and gene ABOUT US | VOYAGER THERAPEUTICS One-Time Delivery. Benefits for a lifetime. PARKINSON’S DISEASE CLINICAL TRIAL The RESTORE-1, Phase 2, randomized, placebo-surgery controlled, double-blinded, multi-center clinical trial was designed to evaluate the safety and efficacy of VY-AADC for the potential treatment of advancing Parkinson’s disease. The RESTORE-1 trial has been placed on clinical hold by the U.S. Food and Drug Administration following

the

FOUNDERS | VOYAGER THERAPEUTICS He is one of the founders of the American Society of Gene and Cell Therapy, served as its president from 2005 to 2006, and was the recipient of the society’s Outstanding Investigator Award in 2013. Dr. Kay received the E. Mead Johnson Award for Research in Pediatrics

in 2000.

CAREERS | VOYAGER THERAPEUTICS Note to Employment Agencies: Please do not forward agency resumes. Voyager Therapeutics is not responsible for any fees related to resumes that are unsolicited and out of executed contracts.

INVESTOR OVERVIEW

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques.

PRESENTATIONS

The Investor Relations website contains information about Voyager Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. ABOUT FRIEDREICH’S ATAXIA AND VY-FXN01 One-Time Delivery. Benefits for a lifetime. PARKINSON’S DISEASE FAQ Parkinson’s disease is a neurological disease that causes symptoms that affect the body’s movement (motor symptoms), including tremors, rigid muscles and an overall slowdown in movement. It primarily affects people who are middle-aged and older. Parkinson’s disease affects approximately 1 million people in the United States and 6

million

MICHAEL HIGGINS

One-Time Delivery. Benefits for a lifetime. VOYAGER THERAPEUTICS & GENZYME ANNOUNCE MAJOR STRATEGIC Up to $845 Million Collaboration to Support Development, Expansion and Commercialization of Voyager’s Novel CNS Product Pipeline. Cambridge, Mass., February 11, 2015 – Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), and Genzyme, a Sanofi company and gene

* __

* __

Toggle navigation

* About Us __

* Who We Are

* Management Team

* Founders

* Board of Directors

* Core Values

* Our Approach

& Programs __

* Gene Therapy

* Pipeline

* Our Programs

* Manufacturing

* Publications & Presentations

* Patients

& Caregivers __

* Parkinson’s Disease FAQ * Parkinson’s Disease Clinical Trial

* Patient Resources

* Expanded Access Policy

* For Investors

& Media __

* Investor Overview

* Stock information

* Press Releases

* Events & Presentations * Corporate Governance * Financial Information

* Annual Reports

* Analyst Coverage

* Investor FAQs

* Contact

* Join

Our Team __

* Who We Are

* Benefits

* Join Us

* Awards

* Contact

Toggle navigation

* About Us __

* Who We Are

* Management Team

* Founders

* Board of Directors

* Core Values

* Our Approach

& Programs __

* Gene Therapy

* Pipeline

* Our Programs

* Manufacturing

* Publications & Presentations

* Patients

& Caregivers __

* Parkinson’s Disease FAQ * Parkinson’s Disease Clinical Trial

* Patient Resources

* Expanded Access Policy

* For Investors

& Media __

* Investor Overview

* Stock information

* Press Releases

* Events & Presentations * Corporate Governance * Financial Information

* Annual Reports

* Analyst Coverage

* Investor FAQs

* Contact

* Join

Our Team __

* Who We Are

* Benefits

* Join Us

* Awards

* Contact

ONE-TIME DELIVERY.

BENEFITS FOR A LIFETIME.

Learn More

SPOTLIGHT

MARCH 9, 2020

AROMATIC L‐AMINO ACID DECARBOXYLASE GENE THERAPY ENHANCES LEVODOPA RESPONSE IN PARKINSON'S DISEASE

JUNE 17, 2019

VOYAGER THERAPEUTICS ANNOUNCES RESTRUCTURED GENE THERAPY RELATIONSHIP WITH SANOFI GENZYME AND PORTFOLIO UPDATE

APRIL 29, 2019

VOYAGER THERAPEUTICS ANNOUNCES NEW DATA IN MULTIPLE PRESENTATIONS AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 2019 ANNUAL MEETING

MARCH 28, 2019

NEUROCRINE BIOSCIENCES AND VOYAGER THERAPEUTICS ANNOUNCE PUBLICATION OF PHASE 1B TRIAL RESULTS OF VY-AADC FOR PARKINSON’S DISEASE IN THE

ANNALS OF NEUROLOGY

JANUARY 29, 2019

NEUROCRINE BIOSCIENCES AND VOYAGER THERAPEUTICS FORM STRATEGIC DEVELOPMENT AND COMMERCIALIZATION COLLABORATION FOR PARKINSON’S DISEASE AND FRIEDREICH’S ATAXIA

MAY 11, 2021

PRECLINICAL DATA PRESENTED AT ASGCT 2021 FEATURED NOVEL, NEXT-GENERATION AAV CAPSIDS

APRIL 26, 2021

VOYAGER THERAPEUTICS RECEIVES FDA CLEARANCE OF IND APPLICATION FOR GENE THERAPY CANDIDATE VY-HTT01 FOR TREATMENT OF HUNTINGTON’S

DISEASE

JULY 30, 2020

DATA-DRIVEN EVOLUTION OF NEUROSURGICAL GENE THERAPY DELIVERY IN PARKINSON’S DISEASE

JULY 20, 2020

CLINICAL OUTCOMES AND SELECTION CRITERIA FOR PRODROMAL HUNTINGTON'S

DISEASE TRIALS

MARCH 9, 2020

AROMATIC L‐AMINO ACID DECARBOXYLASE GENE THERAPY ENHANCES LEVODOPA RESPONSE IN PARKINSON'S DISEASE

JUNE 17, 2019

VOYAGER THERAPEUTICS ANNOUNCES RESTRUCTURED GENE THERAPY RELATIONSHIP WITH SANOFI GENZYME AND PORTFOLIO UPDATE

APRIL 29, 2019

VOYAGER THERAPEUTICS ANNOUNCES NEW DATA IN MULTIPLE PRESENTATIONS AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 2019 ANNUAL MEETING

MARCH 28, 2019

NEUROCRINE BIOSCIENCES AND VOYAGER THERAPEUTICS ANNOUNCE PUBLICATION OF PHASE 1B TRIAL RESULTS OF VY-AADC FOR PARKINSON’S DISEASE IN THE

ANNALS OF NEUROLOGY

JANUARY 29, 2019

NEUROCRINE BIOSCIENCES AND VOYAGER THERAPEUTICS FORM STRATEGIC DEVELOPMENT AND COMMERCIALIZATION COLLABORATION FOR PARKINSON’S DISEASE AND FRIEDREICH’S ATAXIA

MAY 11, 2021

PRECLINICAL DATA PRESENTED AT ASGCT 2021 FEATURED NOVEL, NEXT-GENERATION AAV CAPSIDS

APRIL 26, 2021

VOYAGER THERAPEUTICS RECEIVES FDA CLEARANCE OF IND APPLICATION FOR GENE THERAPY CANDIDATE VY-HTT01 FOR TREATMENT OF HUNTINGTON’S

DISEASE

JULY 30, 2020

DATA-DRIVEN EVOLUTION OF NEUROSURGICAL GENE THERAPY DELIVERY IN PARKINSON’S DISEASE

JULY 20, 2020

CLINICAL OUTCOMES AND SELECTION CRITERIA FOR PRODROMAL HUNTINGTON'S

DISEASE TRIALS

MARCH 9, 2020

AROMATIC L‐AMINO ACID DECARBOXYLASE GENE THERAPY ENHANCES LEVODOPA RESPONSE IN PARKINSON'S DISEASE

prev

next

__ __

WHERE SCIENCE AND PATIENTS CONVERGE Voyager’s mission is to develop and deliver life-changing therapies to people around the world living with severe neurological diseases. This begins with a disciplined commitment to discovery, research, development and manufacturing, and extends to our thoughtful engagement with patients, healthcare providers, caregivers and advocacy organizations.

Learn More

* About Us

* Our Approach

& Programs

* Patients

& Caregivers

* For Investors

& Media

* Join Our

Team

* Contact

� Voyager Therapeutics All rights reserved.

* __ LinkedIn

* __ Twitter

* Terms of Use

* Privacy Notice

* Sitemap